Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
89.68
+1.87 (2.13%)
At close: Dec 12, 2025, 4:00 PM EST
89.69
+0.01 (0.01%)
After-hours: Dec 12, 2025, 7:59 PM EST
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $2.76M in the quarter ending September 30, 2025, a decrease of -26.12%. This brings the company's revenue in the last twelve months to $43.73M, down -50.05% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$43.73M
Revenue Growth
-50.05%
P/S Ratio
168.22
Revenue / Employee
$232,633
Employees
188
Market Cap
7.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
| Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
| Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
| Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
| Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
| Dec 31, 2019 | 2.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KYMR News
- 2 days ago - Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 days ago - Kymera Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 5 days ago - This Drugmaker's Stock Is Soaring Over 40% Monday - Investopedia
- 5 days ago - Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript - Seeking Alpha
- 5 days ago - Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum - Seeking Alpha
- 5 days ago - Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug. - Barrons
- 5 days ago - Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis - GlobeNewsWire
- 8 days ago - Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 - GlobeNewsWire